Long Noncoding RNAs in Myocardial Infarction

2014 ◽  
Vol 6 (247) ◽  
pp. 247ec131-247ec131
Author(s):  
Chester L. Drum
RSC Advances ◽  
2019 ◽  
Vol 9 (61) ◽  
pp. 35624-35635 ◽  
Author(s):  
Hui Zhao ◽  
Li Meng ◽  
Chengyang Xu ◽  
Bin Lin ◽  
Xiangming Zheng ◽  
...  

Long noncoding RNAs have been widely accepted to play important roles in acute myocardial infarction (AMI).


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
C Poller ◽  
A.W Kuss ◽  
S Weiss ◽  
A Haghikia ◽  
M Gast ◽  
...  

Abstract Background Uncontrolled inflammation is a key driver of atherosclerosis, myocardial infarction (MI), and multiple other diseases. Beyond proteins and microRNAs, long noncoding RNAs (lncRNAs) are implicated in inflammation control. We previously reported suppression of lncRNA NEAT1 in circulating immune cells of post-MI patients. In mice lacking lncRNAs NEAT1 or MALAT1 we observed major immune disturbances affecting monocyte-macrophage and T cell differentiation and rendering the immune system unstable and highly vulnerable to immune stress. Here, we report functions of a novel tRNA-type transcript arising from the NEAT1-MALAT1 gene cluster, and on genetic heterogeneity of this region in the human population. Methods and results While previously investigated mice were deficient in the entire NEAT1 or MALAT1 locus, we here aimed to selectively disrupted only the novel 59-nt tRNA-like transcript “menRNA” with hitherto unknown functions. Through CRISPR/Cas9 editing we developed 4 human THP-1 monocyte-macrophage cell line clones with deletions of different extension all of which prevented, however, normal transcript folding and formation of “menRNA”. Transcriptome mapping of all clones by RNA-sequencing identified dysregulation of innate immunity-related genes (IFI16, IFITM3, IRAK3, IRF2BP2, IRF3), chemokine and interleukin receptors (CCR10, IL11RA, IL12RB2, IL23A), cell surface receptors (CD37, CD40LG, CD72, FOCAD, ITGA6, MAEA, THY1), macrophage function-associated genes (ELANE, GRN, MIF, MMP25, MST1P2, PRTN3), tRNA-processing transcripts (GARS, QRSL1P3, QTRT1P1, THG1L, VARS), and small nucleolar RNAs (SNORA26.62.64, SNORD65.112). These data and functional assays indicate functions of NEAT1-derived “menRNA” distinct from those previously described for MALAT1-derived mascRNA. As multiple data suggest inflammation control functions of the NEAT1-MALAT1 region, we investigated the extent of genetic variability of this region in humans. In cohorts from the SHIP study coordinated by the Institute for Community Medicine Greifswald, screening of this region for sequence variants and possible phenotype associations was conducted the results of which are given in Figure 1. Consistent with prior findings, a MALAT1 SNP with very low minor allele frequency (MAF=0.01) was associated (p=0.0062) with systemic low level inflammation (CRP >3.0 mg/L). Unexpected was the association (p<0.01) of eight SNPs (low MAF=0.09 for all) with BMI >35 kg/m2 and LDL >164 mg/dl. Conclusions First, selective disruption of menRNA formation in human monocyte-macrophages provides evidence that this novel type of noncoding RNA has immunoregulatory functions. Second, the phenotype associations of SNPs within the NEAT1-MALAT1 gene cluster warrant further in-depth investigation of the molecular basis of these associations, and of their allele frequencies in cardiovascular disease patient cohorts. The first three and the last authors contributed equally to this work. Figure 1 Funding Acknowledgement Type of funding source: Other. Main funding source(s): “Transcriptome analysis of circulating immune cells to improve the assessment of prognosis and the response to novel anti-inflammatory treatments after myocardial infarction”; DZHK Shared Expertise project B19-006_SE FKZ 81X2100257


2014 ◽  
Vol 115 (7) ◽  
pp. 668-677 ◽  
Author(s):  
Mélanie Vausort ◽  
Daniel R. Wagner ◽  
Yvan Devaux

2020 ◽  
Vol 229 ◽  
pp. 169
Author(s):  
Nurruzanna Ismail ◽  
Siti Aishah Sulaiman ◽  
Noraidatulakma Abdullah ◽  
Nor Azian Abdul Murad ◽  
Rahman Jamal

2019 ◽  
Vol 24 (1) ◽  
Author(s):  
Qingkun Meng ◽  
Zhijun Sun ◽  
Hui Gu ◽  
Jiaying Luo ◽  
Jingjing Wang ◽  
...  

Abstract Background The participation of long noncoding RNAs (lncRNAs) in myocardial infarction has recently been noted. However, their underlying roles in the border zone of myocardial infarction remain unclear. This study uses microarrays to determine the profiles of lncRNAs and mRNAs in the border zone. Methods Bioinformatics methods were employed to uncover their underlying roles. Highly dysregulated lncRNAs was further validated via PCR. Results Four hundred seven lncRNAs and 752 mRNAs were upregulated, while 132 lncRNAs and 547 mRNAs were downregulated in the border zone of myocardial infarction. A circos graph was constructed to visualize the chromosomal distribution and classification of the dysregulated lncRNAs and mRNAs. The upregulated mRNAs in the border zone were most highly enriched in cytokine activity, binding, cytokine receptor binding and related processes, as ascertained through Go analysis. Pathway analysis of the upregulated mRNAs showed the most significant changes were in the TNF signaling pathway, cytokine–cytokine receptor interaction and chemokine signaling pathway and similar pathways and interactions. An lncRNA–mRNA co-expression network was established to probe into the underlying functions of the 10 most highly dysregulated lncRNAs based on their co-expressed mRNAs. In the co-expression network, we found 16 genes directly involved in myocardial infarction, including Alox5ap, Itgb2 and B4galt1. The lncRNAs AY212271, EF424788 and MRAK088538, among others, might be associated with myocardial infarction. BC166504 is probably a key lncRNA in the border zone of myocardial infarction. Conclusions The results may have revealed some aberrantly expressed lncRNAs and mRNAs that contribute to the underlying pathophysiological mechanisms of myocardial infarction.


2017 ◽  
Vol 121 (suppl_1) ◽  
Author(s):  
Viswanathan Rajagopalan ◽  
Emily Schultz ◽  
Youhua Zhang ◽  
Olga Savinova ◽  
Clifford Costello ◽  
...  

Novel mechanisms associated with therapeutically safe thyroid hormone (TH) therapy are emerging. We have shown that oral triiodo-L-thyronine (T3) offers safe cardioprotection in coronary ligation myocardial infarction (MI), ligation ischemia-reperfusion injury, diabetic cardiomyopathy, etc. via restoration of gene expression. However, safe therapeutic effects following atherosclerosis-driven MI and role of long noncoding RNAs (lncRNAs) is unknown. We employed a mouse model of scavenger receptor B1 knockout with hypomorphic apolipoprotein E. Young adult heterozygote littermates served as controls and all mice received high fat (HF) diet for one month. Along with HF diet, a cohort of homozygotes (HypoE) received therapeutic dose of T3 (5.5 μg/kg/d) in drinking water ad libitum. In HypoE mice, Paigen HF diet induced interstitial fibrotic MI with severe hypertrophic (Heart wt./Body wt., HW/BW: control:4.6±0.14; HypoE:12.9±0.75; p<0.0001) heart failure, depressed left ventricular (LV) contractility, increased end-diastolic pressure, myocyte disarray/loss, vacuolization and inflammatory cell infiltration. Aortic root showed atheromatous lipid deposits and median survival time was 26 days. Cholate-free paigen HF diet, used to achieve more gradual transition showed moderate hypertrophy (HW/BW: control:4.9±0.1; HypoE:7.9±0.95; ; p<0.01), decreased LV contractility, increasing atrial effective refractory period with a median survival of 41.5 days. Other changes include decreased serum thyroxine, increased serum cholesterol, significant splenomegaly and alterations in real-time gene expression of numerous cardiac lncRNAs and limited serum lncRNAs involved in inflammatory and immune responses (>2-fold; p<0.05). Oral T3 therapy with cholate-free diet partially restored LV contractility, atrial refractory period and cardiac lncRNAs without significantly affecting serum lncRNAs. These were accompanied by expected feedback inhibition of thyroxine without negatively impacting hypertrophy or heart rate. This is the first study to show a novel role of lncRNAs in TH-mediated cardioprotection. It also demonstrates possibility of safe preventive T3 therapy in a clinically relevant early coronary artery disease model.


2017 ◽  
Vol 69 (11) ◽  
pp. 2036
Author(s):  
Wolfgang Poller ◽  
Martina Gast ◽  
Shinichi Nakagawa ◽  
Jan Haas ◽  
Andrea Stroux ◽  
...  

2019 ◽  
Vol 29 (2) ◽  
pp. 113-121 ◽  
Author(s):  
Xue-ying Zhang ◽  
Lian-wen Zheng ◽  
Chun-jin Li ◽  
Ying Xu ◽  
Xu Zhou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document